Biopharmaceutics Classification System (BCS) / Automated Solubility Apparatus

The FDA Office of Acquisition Grant Services, under the Department of Health and Human Services, is seeking sources for the Biopharmaceutics Classification System (BCS) and an Automated Solubility Apparatus, identified by solicitation number 75F40126SS131706, posted on July 6, 2026, with responses due by July 16, 2026. This sources sought notice is classified under NAICS code 334516 and is intended to gather market information to support future procurement decisions, with no set-aside designation specified. The contract’s performance location is in Silver Spring, Maryland, while the office responsible is located in Rockville, Maryland, and all inquiries should be directed to Howard Nesmith, the primary point of contact, via email or phone. The procurement is focused on advanced laboratory equipment and systems related to the Biopharmaceutics Classification System, which is essential for evaluating drug solubility and permeability characteristics critical to regulatory assessment and pharmaceutical development. The Automated Solubility Apparatus must meet specific technical criteria for precision, reproducibility, and integration with existing analytical workflows within the FDA’s operational environment. While this notice does not constitute a solicitation for proposals or a guaranteed award, it seeks input from qualified vendors to assess industry capabilities, emerging technologies, and potential sources that align with the FDA’s scientific and operational needs. Respondents are encouraged to provide detailed information on product specifications, availability, delivery timelines, and technical support services relevant to the designated equipment.